The cost-effectiveness and value of information of three influenza vaccination dosing strategies for individuals with human immunodeficiency virus.
Identifieur interne : 000473 ( Main/Exploration ); précédent : 000472; suivant : 000474The cost-effectiveness and value of information of three influenza vaccination dosing strategies for individuals with human immunodeficiency virus.
Auteurs : Bohdan Nosyk [Canada] ; Behnam Sharif ; Huiying Sun ; Curtis Cooper ; Aslam H. AnisSource :
- PloS one [ 1932-6203 ] ; 2011.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Analyse coût-bénéfice, Calendrier d'administration des médicaments, Canada, Chaines de Markov, Contrôle des maladies contagieuses (), Femelle, Grippe humaine (), Humains, Infections à VIH (), Infections à VIH (virologie), Injections musculaires, Mâle, Programmes de vaccination, Études de cohortes.
- MESH :
- virologie : Infections à VIH.
- Adulte, Adulte d'âge moyen, Analyse coût-bénéfice, Calendrier d'administration des médicaments, Canada, Chaines de Markov, Contrôle des maladies contagieuses, Femelle, Grippe humaine, Humains, Infections à VIH, Injections musculaires, Mâle, Programmes de vaccination, Études de cohortes.
- Wicri :
- geographic : Canada.
English descriptors
- KwdEn :
- Adult, Canada, Cohort Studies, Communicable Disease Control (methods), Cost-Benefit Analysis, Drug Administration Schedule, Female, HIV Infections (complications), HIV Infections (virology), Humans, Immunization Programs, Influenza, Human (complications), Influenza, Human (prevention & control), Injections, Intramuscular, Male, Markov Chains, Middle Aged.
- MESH :
- geographic : Canada.
- complications : HIV Infections, Influenza, Human.
- methods : Communicable Disease Control.
- prevention & control : Influenza, Human.
- virology : HIV Infections.
- Adult, Cohort Studies, Cost-Benefit Analysis, Drug Administration Schedule, Female, Humans, Immunization Programs, Injections, Intramuscular, Male, Markov Chains, Middle Aged.
Abstract
BACKGROUND
Influenza vaccine immunogenicity is diminished in patients living with HIV/AIDS. We evaluated the cost-effectiveness and expected value of perfect information (EVPI) of three alternative influenza vaccine dosing strategies intended to increase immunogenicity in those patients.
METHODS
A randomized, multi-centered, controlled, vaccine trial was conducted at 12 CIHR Canadian HIV Trials Network sites. Three dosing strategies with seasonal, inactivated trivalent, non-adjuvanted intramuscular vaccine were used in HIV infected adults: two standard doses over 28 days (Strategy A), two double doses over 28 days (Strategy B) and a single standard dose of influenza vaccine (Strategy C), administered prior to the 2008 influenza season. The comparator in our analysis was practice in the previous year, in which 82.8% of HIV/AIDS received standard-dose vaccination (Strategy D). A Markov cohort model was developed to estimate the monthly probability of Influenza-like Illness (ILI) over one influenza season. Costs and quality-adjusted life years, extrapolated to the lifetime of the hypothetical study cohorts, were estimated in calculating incremental cost-effectiveness ratios (ICER) and EVPI in conducting further research.
RESULTS
298 patients with median CD4 of 470 cells/µl and 76% with viral load suppression were randomized. Strategy C was the most cost-effective strategy for the overall trial population and for suppressed and unsuppressed individuals. Mean ICERs for Strategy A for unsuppressed patients could also be considered cost-effective. The level of uncertainty regarding the decision to implement strategy A versus C for unsuppressed individuals was high. The maximum acceptable cost of reducing decision uncertainty in implementing strategy A for individuals with unsuppressed pVL was $418,000--below the cost of conducting a larger-scale trial.
CONCLUSION
Our results do not support a policy to implement increased antigen dose or booster dosing strategies with seasonal, inactivated trivalent, non-adjuvanted intramuscular vaccine for individuals with HIV in Canada.
TRIAL REGISTRATION
ClinicalTrials.gov NCT00764998.
DOI: 10.1371/journal.pone.0027059
PubMed: 22162988
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The cost-effectiveness and value of information of three influenza vaccination dosing strategies for individuals with human immunodeficiency virus.</title><author><name sortKey="Nosyk, Bohdan" sort="Nosyk, Bohdan" uniqKey="Nosyk B" first="Bohdan" last="Nosyk">Bohdan Nosyk</name><affiliation wicri:level="1"><nlm:affiliation>CIHR Canadian HIV Trials Network, Vancouver, British Columbia, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>CIHR Canadian HIV Trials Network, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Sharif, Behnam" sort="Sharif, Behnam" uniqKey="Sharif B" first="Behnam" last="Sharif">Behnam Sharif</name></author><author><name sortKey="Sun, Huiying" sort="Sun, Huiying" uniqKey="Sun H" first="Huiying" last="Sun">Huiying Sun</name></author><author><name sortKey="Cooper, Curtis" sort="Cooper, Curtis" uniqKey="Cooper C" first="Curtis" last="Cooper">Curtis Cooper</name></author><author><name sortKey="Anis, Aslam H" sort="Anis, Aslam H" uniqKey="Anis A" first="Aslam H" last="Anis">Aslam H. Anis</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:22162988</idno><idno type="pmid">22162988</idno><idno type="doi">10.1371/journal.pone.0027059</idno><idno type="wicri:Area/Main/Corpus">000472</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000472</idno><idno type="wicri:Area/Main/Curation">000472</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000472</idno><idno type="wicri:Area/Main/Exploration">000472</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The cost-effectiveness and value of information of three influenza vaccination dosing strategies for individuals with human immunodeficiency virus.</title><author><name sortKey="Nosyk, Bohdan" sort="Nosyk, Bohdan" uniqKey="Nosyk B" first="Bohdan" last="Nosyk">Bohdan Nosyk</name><affiliation wicri:level="1"><nlm:affiliation>CIHR Canadian HIV Trials Network, Vancouver, British Columbia, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>CIHR Canadian HIV Trials Network, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Sharif, Behnam" sort="Sharif, Behnam" uniqKey="Sharif B" first="Behnam" last="Sharif">Behnam Sharif</name></author><author><name sortKey="Sun, Huiying" sort="Sun, Huiying" uniqKey="Sun H" first="Huiying" last="Sun">Huiying Sun</name></author><author><name sortKey="Cooper, Curtis" sort="Cooper, Curtis" uniqKey="Cooper C" first="Curtis" last="Cooper">Curtis Cooper</name></author><author><name sortKey="Anis, Aslam H" sort="Anis, Aslam H" uniqKey="Anis A" first="Aslam H" last="Anis">Aslam H. Anis</name></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Canada</term><term>Cohort Studies</term><term>Communicable Disease Control (methods)</term><term>Cost-Benefit Analysis</term><term>Drug Administration Schedule</term><term>Female</term><term>HIV Infections (complications)</term><term>HIV Infections (virology)</term><term>Humans</term><term>Immunization Programs</term><term>Influenza, Human (complications)</term><term>Influenza, Human (prevention & control)</term><term>Injections, Intramuscular</term><term>Male</term><term>Markov Chains</term><term>Middle Aged</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse coût-bénéfice</term><term>Calendrier d'administration des médicaments</term><term>Canada</term><term>Chaines de Markov</term><term>Contrôle des maladies contagieuses ()</term><term>Femelle</term><term>Grippe humaine ()</term><term>Humains</term><term>Infections à VIH ()</term><term>Infections à VIH (virologie)</term><term>Injections musculaires</term><term>Mâle</term><term>Programmes de vaccination</term><term>Études de cohortes</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Canada</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Communicable Disease Control</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Cohort Studies</term><term>Cost-Benefit Analysis</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Immunization Programs</term><term>Injections, Intramuscular</term><term>Male</term><term>Markov Chains</term><term>Middle Aged</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse coût-bénéfice</term><term>Calendrier d'administration des médicaments</term><term>Canada</term><term>Chaines de Markov</term><term>Contrôle des maladies contagieuses</term><term>Femelle</term><term>Grippe humaine</term><term>Humains</term><term>Infections à VIH</term><term>Injections musculaires</term><term>Mâle</term><term>Programmes de vaccination</term><term>Études de cohortes</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Influenza vaccine immunogenicity is diminished in patients living with HIV/AIDS. We evaluated the cost-effectiveness and expected value of perfect information (EVPI) of three alternative influenza vaccine dosing strategies intended to increase immunogenicity in those patients.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>A randomized, multi-centered, controlled, vaccine trial was conducted at 12 CIHR Canadian HIV Trials Network sites. Three dosing strategies with seasonal, inactivated trivalent, non-adjuvanted intramuscular vaccine were used in HIV infected adults: two standard doses over 28 days (Strategy A), two double doses over 28 days (Strategy B) and a single standard dose of influenza vaccine (Strategy C), administered prior to the 2008 influenza season. The comparator in our analysis was practice in the previous year, in which 82.8% of HIV/AIDS received standard-dose vaccination (Strategy D). A Markov cohort model was developed to estimate the monthly probability of Influenza-like Illness (ILI) over one influenza season. Costs and quality-adjusted life years, extrapolated to the lifetime of the hypothetical study cohorts, were estimated in calculating incremental cost-effectiveness ratios (ICER) and EVPI in conducting further research.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>298 patients with median CD4 of 470 cells/µl and 76% with viral load suppression were randomized. Strategy C was the most cost-effective strategy for the overall trial population and for suppressed and unsuppressed individuals. Mean ICERs for Strategy A for unsuppressed patients could also be considered cost-effective. The level of uncertainty regarding the decision to implement strategy A versus C for unsuppressed individuals was high. The maximum acceptable cost of reducing decision uncertainty in implementing strategy A for individuals with unsuppressed pVL was $418,000--below the cost of conducting a larger-scale trial.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Our results do not support a policy to implement increased antigen dose or booster dosing strategies with seasonal, inactivated trivalent, non-adjuvanted intramuscular vaccine for individuals with HIV in Canada.</p></div><div type="abstract" xml:lang="en"><p><b>TRIAL REGISTRATION</b></p><p>ClinicalTrials.gov NCT00764998.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22162988</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>12</Issue><PubDate><Year>2011</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>The cost-effectiveness and value of information of three influenza vaccination dosing strategies for individuals with human immunodeficiency virus.</ArticleTitle><Pagination><MedlinePgn>e27059</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0027059</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Influenza vaccine immunogenicity is diminished in patients living with HIV/AIDS. We evaluated the cost-effectiveness and expected value of perfect information (EVPI) of three alternative influenza vaccine dosing strategies intended to increase immunogenicity in those patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A randomized, multi-centered, controlled, vaccine trial was conducted at 12 CIHR Canadian HIV Trials Network sites. Three dosing strategies with seasonal, inactivated trivalent, non-adjuvanted intramuscular vaccine were used in HIV infected adults: two standard doses over 28 days (Strategy A), two double doses over 28 days (Strategy B) and a single standard dose of influenza vaccine (Strategy C), administered prior to the 2008 influenza season. The comparator in our analysis was practice in the previous year, in which 82.8% of HIV/AIDS received standard-dose vaccination (Strategy D). A Markov cohort model was developed to estimate the monthly probability of Influenza-like Illness (ILI) over one influenza season. Costs and quality-adjusted life years, extrapolated to the lifetime of the hypothetical study cohorts, were estimated in calculating incremental cost-effectiveness ratios (ICER) and EVPI in conducting further research.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">298 patients with median CD4 of 470 cells/µl and 76% with viral load suppression were randomized. Strategy C was the most cost-effective strategy for the overall trial population and for suppressed and unsuppressed individuals. Mean ICERs for Strategy A for unsuppressed patients could also be considered cost-effective. The level of uncertainty regarding the decision to implement strategy A versus C for unsuppressed individuals was high. The maximum acceptable cost of reducing decision uncertainty in implementing strategy A for individuals with unsuppressed pVL was $418,000--below the cost of conducting a larger-scale trial.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results do not support a policy to implement increased antigen dose or booster dosing strategies with seasonal, inactivated trivalent, non-adjuvanted intramuscular vaccine for individuals with HIV in Canada.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT00764998.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nosyk</LastName><ForeName>Bohdan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>CIHR Canadian HIV Trials Network, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharif</LastName><ForeName>Behnam</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Huiying</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Anis</LastName><ForeName>Aslam H</ForeName><Initials>AH</Initials></Author><Author ValidYN="Y"><CollectiveName>CIHR Canadian HIV Trials Network Influenza Vaccine Research Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00764998</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>12</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003140" MajorTopicYN="N">Communicable Disease Control</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="Y">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017589" MajorTopicYN="N">Immunization Programs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007273" MajorTopicYN="N">Injections, Intramuscular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008390" MajorTopicYN="N">Markov Chains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Cooper</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohen</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conway</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boivin</LastName><ForeName>Guy</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haase</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>Marianne</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kilby</LastName><ForeName>Don</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klein</LastName><ForeName>Marina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markanday</LastName><ForeName>Anurag</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rachlis</LastName><ForeName>Anita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shafran</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smieja</LastName><ForeName>Marek</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walmsley</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thorne</LastName><ForeName>Anona</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singer</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zubyk</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seguin</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mills</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Halperin</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>05</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22162988</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0027059</ArticleId><ArticleId IdType="pii">PONE-D-11-09949</ArticleId><ArticleId IdType="pmc">PMC3232195</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>PLoS One. 2011;6(3):e17758</Citation><ArticleIdList><ArticleId IdType="pubmed">21512577</ArticleId></ArticleIdList></Reference><Reference><Citation>Biologicals. 2009 Aug;37(4):216-21</Citation><ArticleIdList><ArticleId IdType="pubmed">19268607</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2002 Jun 7;20(19-20):2562-78</Citation><ArticleIdList><ArticleId IdType="pubmed">12057614</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Gerontol. 2004 Oct;39(10):1447-58</Citation><ArticleIdList><ArticleId IdType="pubmed">15501014</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011;6(1):e16496</Citation><ArticleIdList><ArticleId IdType="pubmed">21304982</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):167-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15905732</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 2005;23(1):47-54</Citation><ArticleIdList><ArticleId IdType="pubmed">15693727</ArticleId></ArticleIdList></Reference><Reference><Citation>Value Health. 2005 Sep-Oct;8(5):521-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16176491</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Sep 12;26 Suppl 4:D17-22</Citation><ArticleIdList><ArticleId IdType="pubmed">19230153</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Recomm Rep. 1999 Apr 30;48(RR-4):1-28</Citation><ArticleIdList><ArticleId IdType="pubmed">10366138</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2006;6:138</Citation><ArticleIdList><ArticleId IdType="pubmed">16965629</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):631-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19430303</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2000 Jul 1;18(26):3040-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10825608</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS. 2010 Oct 23;24(16):2461-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20827165</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Biol (Basel). 2003;115:63-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15088777</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2001 Feb 12;161(3):441-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11176770</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Life Res. 2009 Sep;18(7):815-24</Citation><ArticleIdList><ArticleId IdType="pubmed">19562514</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 2004 Jul;103(1-2):125-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15163500</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Technol Assess Health Care. 2008 Winter;24(1):112-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18218176</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Public Health. 1993 Dec;83(12):1712-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8259800</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Infect Dis Med Microbiol. 2008 Nov;19(6):419-23</Citation><ArticleIdList><ArticleId IdType="pubmed">19436572</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2007 Jul 15;45(2):234-40</Citation><ArticleIdList><ArticleId IdType="pubmed">17578785</ArticleId></ArticleIdList></Reference><Reference><Citation>CMAJ. 2001 Aug 21;165(4):415-20</Citation><ArticleIdList><ArticleId IdType="pubmed">11531049</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS. 2010 Nov 13;24(17):2705-15</Citation><ArticleIdList><ArticleId IdType="pubmed">20859193</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2001 Jun 15;32(12):1784-91</Citation><ArticleIdList><ArticleId IdType="pubmed">11360221</ArticleId></ArticleIdList></Reference><Reference><Citation>HIV Med. 2008 Jan;9(1):57-61</Citation><ArticleIdList><ArticleId IdType="pubmed">18199173</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 2008;26(3):191-215</Citation><ArticleIdList><ArticleId IdType="pubmed">18282015</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS. 2008 Jan 30;22(3):349-56</Citation><ArticleIdList><ArticleId IdType="pubmed">18195561</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2008 Feb 15;197(4):490-502</Citation><ArticleIdList><ArticleId IdType="pubmed">18275271</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS. 2007 May 31;21(9):1185-97</Citation><ArticleIdList><ArticleId IdType="pubmed">17502729</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2009 Jan;3(1):37-49</Citation><ArticleIdList><ArticleId IdType="pubmed">19453440</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2006 May 15;25(9):1485-97</Citation><ArticleIdList><ArticleId IdType="pubmed">16158409</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Sci Med. 2006 May;62(9):2091-100</Citation><ArticleIdList><ArticleId IdType="pubmed">16325975</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Anis, Aslam H" sort="Anis, Aslam H" uniqKey="Anis A" first="Aslam H" last="Anis">Aslam H. Anis</name><name sortKey="Cooper, Curtis" sort="Cooper, Curtis" uniqKey="Cooper C" first="Curtis" last="Cooper">Curtis Cooper</name><name sortKey="Sharif, Behnam" sort="Sharif, Behnam" uniqKey="Sharif B" first="Behnam" last="Sharif">Behnam Sharif</name><name sortKey="Sun, Huiying" sort="Sun, Huiying" uniqKey="Sun H" first="Huiying" last="Sun">Huiying Sun</name></noCountry><country name="Canada"><noRegion><name sortKey="Nosyk, Bohdan" sort="Nosyk, Bohdan" uniqKey="Nosyk B" first="Bohdan" last="Nosyk">Bohdan Nosyk</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000473 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000473 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeCanadaV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22162988
|texte= The cost-effectiveness and value of information of three influenza vaccination dosing strategies for individuals with human immunodeficiency virus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22162988" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV3
| This area was generated with Dilib version V0.6.35. |  |